Castle Hook Partners LP Makes New Investment in Danaher Corporation $DHR

Castle Hook Partners LP purchased a new position in Danaher Corporation (NYSE:DHR) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,152,081 shares of the conglomerate’s stock, valued at approximately $263,734,000. Danaher makes up approximately 1.1% of Castle Hook Partners LP’s investment portfolio, making the stock its 10th biggest holding. Castle Hook Partners LP owned about 0.16% of Danaher as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. JPL Wealth Management LLC purchased a new stake in Danaher in the 3rd quarter worth $25,000. Elevated Capital Advisors LLC bought a new stake in shares of Danaher in the 4th quarter worth about $26,000. WFA of San Diego LLC bought a new stake in shares of Danaher in the 2nd quarter worth about $26,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Danaher in the 3rd quarter worth about $27,000. Finally, Hilton Head Capital Partners LLC bought a new stake in shares of Danaher in the 4th quarter worth about $27,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on DHR shares. Wolfe Research downgraded shares of Danaher from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. UBS Group reduced their target price on shares of Danaher from $270.00 to $250.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Barclays reduced their target price on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. DZ Bank started coverage on shares of Danaher in a report on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 target price on the stock. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Danaher in a report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $233.61.

Danaher Stock Performance

Shares of NYSE:DHR opened at $177.85 on Thursday. The company has a market capitalization of $125.88 billion, a price-to-earnings ratio of 34.40, a PEG ratio of 2.31 and a beta of 0.81. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The firm’s 50-day moving average is $180.26 and its 200 day moving average is $203.59. The company has a current ratio of 1.87, a quick ratio of 1.52 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, April 20th. The conglomerate reported $2.06 EPS for the quarter, beating the consensus estimate of $1.94 by $0.12. The company had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm’s revenue was up 3.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.88 EPS. Research analysts predict that Danaher Corporation will post 8.45 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, June 26th. Danaher’s payout ratio is 30.95%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.